Clinical Validation of Non-Invasive Prenatal Testing for Fetal Common Aneuploidies in 1,055 Korean Pregnant Women: a Single Center Experience
10.3346/jkms.2019.34.e172
- Author:
Da Eun LEE
1
;
Hyunjin KIM
;
Jungsun PARK
;
Taegyun YUN
;
Dong Yoon PARK
;
Minhyoung KIM
;
Hyun Mee RYU
Author Information
1. Laboratory of Medical Genetics, Medical Research Institute, Cheil General Hospital and Women's Healthcare Center, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Prenatal Screening;
Cell-free DNA;
Massively Parallel Sequencing
- MeSH:
Aneuploidy;
Chromosome Aberrations;
DNA;
Down Syndrome;
Female;
Fetus;
High-Throughput Nucleotide Sequencing;
Humans;
Karyotype;
Plasma;
Pregnancy;
Pregnant Women;
Prenatal Diagnosis;
Prospective Studies;
Retrospective Studies;
Sensitivity and Specificity;
Trisomy
- From:Journal of Korean Medical Science
2019;34(24):e172-
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Non-invasive prenatal testing (NIPT) using cell-free fetal DNA from maternal plasma for fetal aneuploidy identification is expanding worldwide. The objective of this study was to evaluate the clinical utility of NIPT for the detection of trisomies 21, 18, and 13 of high-risk fetus in a large Korean population. METHODS: This study was performed retrospectively, using stored maternal plasma from 1,055 pregnant women with singleton pregnancies who underwent invasive prenatal diagnosis because of a high-risk indication for chromosomal abnormalities. The NIPT results were confirmed by karyotype analysis. RESULTS: Among 1,055 cases, 108 cases of fetal aneuploidy, including trisomy 21 (n = 57), trisomy 18 (n = 42), and trisomy 13 (n = 9), were identified by NIPT. In this study, NIPT showed 100% sensitivity and 99.9% specificity for trisomy 21, and 92.9% sensitivity and 100% specificity for trisomy 18, and 100% sensitivity and 99.9% specificity for trisomy 13. The overall positive predictive value (PPV) was 98.1%. PPVs for trisomies 21, 18, and 13 ranged from 90.0% to 100%. CONCLUSION: This study demonstrates that our NIPT technology is reliable and accurate when applied to maternal DNA samples collected from pregnant women. Further large prospective studies are needed to adequately assess the performance of NIPT.
